Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of MRI Labeling Technique to Track Mesenchymal Stem Cell Survival in Orthopaedic Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03648463
Recruitment Status : Not yet recruiting
First Posted : August 27, 2018
Last Update Posted : March 28, 2019
Sponsor:
Information provided by (Responsible Party):
Jason L. Dragoo, Stanford University

Brief Summary:

The primary objective is to determine whether a surgical intervention involving removing of the calcified cartilage cap in patients with Grade II Kellgren-Lawrence osteoarthritis influences the incorporation of labeled bone marrow aspirate concentrate (BMAC)-derived cells within the cartilage regenerate vs labeled BMAC cells delivered after arthroscopy without removing of the calcified cartilaginous layer. The survival and incorporation of the BMAC labeled cells will be evaluated with MRI using the Ferumoxytol infusion stem cell labeling technique. The second arm of the study evaluating cell fate after injecting stem cells under a rotator cuff repair will also be explored.

The secondary objectives are to 1) determine which surgical intervention leads to better clinical outcomes as measured by Knee Injury and Osteoarthritis Outcome Score (KOOS) at 12 months, and 2) determine who long we can track the labeled-BMAC cells in the knee.


Condition or disease Intervention/treatment Phase
Cartilage Degeneration Rotator Cuff Tear Osteoarthritis, Knee Procedure: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection Not Applicable

Detailed Description:

Articular cartilage repair and regeneration has become a focal point for scientists and surgeons in search for a biological treatment for osteoarthritis that has failed non-operative management. Surgeons have begun to harvest and centrifuged bone marrow aspirate to produce bone marrow aspirate concentrate (BMAC) in hopes that the mesenchymal stem cells in the bone marrow aspirate can stimulate cartilage regeneration in areas of articular cartilage deficiency. This study is a first-in-human blinded randomized clinical trial using labeled BMAC cells in adults diagnosed with grade II-III Kellgren-Lawrence osteoarthritis.

This is a single site study where 20 cases among eligible patients will be identified and randomly assigned to either the control (no calcified cartilage) or experimental (calcified cartilage removed) group. A power analysis will be performed after 20 patients to determine the total number of patients required to reach adequate power.

A patient will receive an infusion of Feraheme 2 days before the procedure and a baseline MR Pelvis and knee. A nurse will be present at all times during the infusion to monitor vitals. On the day of the procedure patient will undergo harvesting of the bone marrow from the pelvis and arthroscopy procedure involving menisectomy, synovectomy and debridement. Patients in the experimental group will also undergo removal of the calcified cartilage cap. The bone marrow aspirate will be centrifuged and about 5-7 cc of BMAC injected into knee. MRIs will be done at the 2 day mark for confirmation of the labeling of the mesenchymal cells, and at the two week and 3 month mark. Patient related Outcomes will be measured using the Knee injury and Osteoarthritis Score at 12 months follow up.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Patients will not know if they received the surgical intervention that entails removing of the calcified cartilage or not.
Primary Purpose: Treatment
Official Title: Effect of Surgical Intervention on Mesenchymal Stem Cell Survival in Soft Tissue Reconstructive Procedures Using a Novel MRI Labeling Technique
Estimated Study Start Date : October 1, 2019
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: arthroscopy with removal of calcified cartilage
This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) along with removal of the calcified cartilage layer. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
Procedure: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection
Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)
Other Name: Injection of bone marrow aspirate concentrate harvested from the patient's iliac crest (produced using the Harvest/Terumo BCT system)

Active Comparator: arthroscopy without removal of calcified cartilage
This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) but with retention of the calcified cartilage cap. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
Procedure: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection
Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)
Other Name: Injection of bone marrow aspirate concentrate harvested from the patient's iliac crest (produced using the Harvest/Terumo BCT system)




Primary Outcome Measures :
  1. Integration of the mesenchymal stem cells. [ Time Frame: 3 months ]
    Number of integrated labeled mesenchymal stem cells in the cartilage regenerate counted from from MRI imaging.


Secondary Outcome Measures :
  1. Knee Injury and Osteoarthritis Outcome Score (pain subscale) [ Time Frame: 12 months ]
    KOOS pain score at baseline and at 12 months to measure functional outcomes. This sub scale of the KOOS questionnaire has a possible total of 100 points (higher scores mean less pain)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adults aged 30-70 patients with Kellgren grade II-III osteoarthritis,
  2. Symptomatic knee pain greater than 6 months
  3. At least one discrete contained chondral defect
  4. Failed a minimum of 6 weeks of physical therapy
  5. Grossly normal knee alignment: <5 degrees of varus or valgus alignment
  6. Lesion located on medial or lateral femoral condyle or trochlea

Exclusion Criteria:

  1. Radiographs demonstrating either no or little osteoarthritis (Kellgren-Lawrence Grade 0 or 1)
  2. Diagnosis of Inflammatory (RA, JIA etc) or infectious arthritis
  3. Malalignment of mechanical axis > or = 5 degrees of varus/valgus
  4. Cortisone and/or Hyaluronic acid intra-articular injection within the last 3 months
  5. Ligamentous knee instability
  6. The subject is on ongoing specific osteoarthritis drugs such as chondroitin sulphate, diacerein, N-glucosamine, piascledine, capsaicin in the 2 weeks prior to baseline treatment
  7. BMI > 30
  8. Currently pregnant or planning to become pregnant (no MRI possible).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03648463


Contacts
Layout table for location contacts
Contact: Michelle Backer 650 721-7653 mbacker@stanford.edu

Sponsors and Collaborators
Stanford University
Investigators
Layout table for investigator information
Principal Investigator: Jason L Dragoo, MD Stanford University

Layout table for additonal information
Responsible Party: Jason L. Dragoo, Principal Investigator, Stanford University
ClinicalTrials.gov Identifier: NCT03648463     History of Changes
Other Study ID Numbers: IRB-46711
First Posted: August 27, 2018    Key Record Dates
Last Update Posted: March 28, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Rotator Cuff Injuries
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Rupture
Wounds and Injuries
Shoulder Injuries
Tendon Injuries